FTC insists generics ANI and Novitium divest IP before merger

The Federal Trade Commission (FTC) has stipulated that generic drug marketers ANI Pharmaceuticals, and Novitium Pharma must divest IP rights to Prasco ahead of their $210 million merger.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

USPTO director steps into Sun Pharma’s PTAB-ITC clash

31 July 2026 A director review has overturned a PTAB ruling, questioning why it diverged from an ITC decision based on the same patent claims, prior art and evidence.

Careers

USPTO appoints new acting commissioner for patents

31 July 2026 The ex-Greenberg Traurig shareholder will oversee the office’s 14,000-strong patent division, as the agency prepares for the departure of deputy director Coke Morgan Stewart.

MedTech

European court strikes down hearing aid sensor patent

30 July 2026 A dispute over optical sensor technology in miniature hearing devices ended with the EPO revoking a patent, finding the invention obvious despite ruling it was new over the closest prior art.

More features

USPTO director steps into Sun Pharma’s PTAB-ITC clash

USPTO appoints new acting commissioner for patents

European court strikes down hearing aid sensor patent

Where Big Pharma is betting big in the M&A boom

Fish & Richardson adds AI and medical device specialist

Boston Scientific overturns $42m patent verdict on appeal

Buying the brains: Why is Big Pharma shopping for innovation?

FisherBroyles and Hong Kong affiliate draft in senior partners

FTC insists generics ANI and Novitium divest IP before merger

More on this story

Editor's picks

Editor's picks

More features